2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

4:30PM-6:00PM: Abstract Number: 2864

Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time

Rheumatoid Arthritis – Clinical Aspects V: Predicting Treatment Response

4:30PM-6:00PM: Abstract Number: 2871

Anti-RA33 (hnRNP-A2/B1) Autoantibodies Are Associated with the Therapeutic Response to Methotrexate and Anti-TNF Treatment in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Pharmacodynamic Markers and Therapeutic Intervention

4:30PM-6:00PM: Abstract Number: 2838

Apoptotic Bodies Containing dsDNA Covalently Modified By Parvovirus B19 Non-Structural Protein NS1 Induce dsDNA Autoantibodies and End Organ Damage in Non-Autoimmune Mice

Infection-related Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 2845

Association between Serum Urate As a Surrogate Endpoint and Flares in People with Gout: An Ecological Study Based on a Systematic Review of Trials and Open Label Extensions

Metabolic and Crystal Arthropathies I: Gout Risk of Disease Activity, Cardiovascular Disease and Mortality

4:30PM-6:00PM: Abstract Number: 2819

Association of Socioeconomic Status with Osteoarthritis-Induced Disability Progression

ARHP: Exemplary Abstracts

4:30PM-6:00PM: Abstract Number: 2846

Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Renal-Related and Decreased Risk of Dementia-Related Death

Metabolic and Crystal Arthropathies I: Gout Risk of Disease Activity, Cardiovascular Disease and Mortality

4:30PM-6:00PM: Abstract Number: 2867

CD39 Positive Regulatory T Cells As a Biomarker of Responsiveness to Methotrexate in Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Pharmacodynamic Markers and Therapeutic Intervention

4:30PM-6:00PM: Abstract Number: 2880

Clinical Evolution of Patients with Inflammatory Back Pain: A Population-Based Longitudinal Cohort Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV

4:30PM-6:00PM: Abstract Number: 2840

Clinical Presentation and Outcomes in Patients with Prosthetic Joint Septic Arthritis Who Had One-Stage Versus Two-Stage Joint Replacement

Infection-related Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 2829

Complete Epigenetic Landscape of Rheumatoid Arthritis Fibroblast-like Synoviocytes Reveals Unanticipated Critical Pathogenic Pathways

Genetics, Genomics and Proteomics

4:30PM-6:00PM: Abstract Number: 2888

Corticosteroid-Sparing Benefit of Intravenous Immunoglobulins in Systemic Sclerosis-Associated Inflammatory Myopathy: A Retrospective Study of 54 Patients

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics II

4:30PM-6:00PM: Abstract Number: 2833

Cost-Effectiveness of Competing Anticoagulation Strategies in Knee Replacement Patients

Health Services Research I: Cost Drivers in Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 2837

Cross-Sectional Analysis of Chikungunya Arthritis Patients 22-Months Post-Infection Demonstrates a Lack of Viral Persistence in Synovial Fluid

Infection-related Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 2859

Development of New Juvenile Arthritis Disease Activity Score Cut-Offs for Oligoarthritis and RF-Negative Polyarthritis from a Large Multinational Cohort of Children with Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Juvenile Arthritis

4:30PM-6:00PM: Abstract Number: 2820

Disease Activity By the Sledai in Lupus Patients Who Self Report Sleep Disturbance and Sleep Impairment Using the Patient-Reported Outcomes Measurement Information System Instruments

ARHP: Exemplary Abstracts

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].